---
title: "SL PHARM: The invested company Changfeng Pharmaceutical plans to go public in Hong Kong on October 8"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/259470551.md"
description: "SL PHARM announced that its associate company Changfeng Pharmaceutical is expected to be listed in Hong Kong on October 8, 2025, with a stock code and a global offering of 41.198 million shares at an issue price of HKD 14.75. SL PHARM holds a 3.68% stake in Changfeng Pharmaceutical, with a lock-up period of 12 months. The listing is expected to have a positive impact on SL PHARM's financial and operational results, and investors should be aware of the risks"
datetime: "2025-09-30T07:45:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/259470551.md)
  - [en](https://longbridge.com/en/news/259470551.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/259470551.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/259470551.md) | [English](https://longbridge.com/en/news/259470551.md)


# SL PHARM: The invested company Changfeng Pharmaceutical plans to go public in Hong Kong on October 8

Beijing SL PHARM Co., Ltd. announced that its associate company Changfeng Pharmaceutical Co., Ltd. is expected to be listed on the main board of the Hong Kong Stock Exchange on October 8, 2025, with the stock code 02652.HK. A total of 41.198 million shares will be globally offered at a price of HKD 14.75 per share. Upon completion of the offering, SL PHARM will hold 15.165653 million shares of Changfeng Pharmaceutical, expected to account for 3.68% of the total shares after issuance, with a lock-up period of 12 months. According to regulations, SL PHARM will classify its equity in Changfeng Pharmaceutical as related financial assets. The listing of Changfeng Pharmaceutical is expected to have a positive impact on SL PHARM's financial and operational results in 2025, subject to the audit results, and investors are reminded to pay attention to risks

### 相關股票

- [SL PHARM (002038.CN)](https://longbridge.com/zh-HK/quote/002038.CN.md)

## 相關資訊與研究

- [Know a rising star in pharma marketing? Nominate them here](https://longbridge.com/zh-HK/news/278461777.md)
- [Kelun-Biotech Sets March 2026 Board Meeting and Webcast for 2025 Results](https://longbridge.com/zh-HK/news/278713493.md)
- [16:44 ETEntwickelt für die Praxis: XCMG stellt auf der CONEXPO 2026 erstmals eine Bagger-Baureihe für Nordamerika vor](https://longbridge.com/zh-HK/news/278614033.md)
- [03:24 ETXCMG Crane Debuts Three U.S.- Tailored Cranes at CONEXPO 2026](https://longbridge.com/zh-HK/news/278508503.md)
- [11:15 ETInventHelp Inventor Develops New Brake Warning System (RIM-342)](https://longbridge.com/zh-HK/news/278746531.md)